Press release
Increase In Prevalence Of Multiple Myeloma Globally Is Expected To Support Growth Of Bcma Targeted Therapies Market
B-Cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells. The expression profiles exhibited by TACI and BAFF-R are comparatively lower than that of the BCMA in multiple myeloma patients. Also, these antigens are hardly detected in the malignant plasma cells thus suggesting BCMA to be a standard choice over the other targeting antigens. The expression of BCMA gradually increases with the progression from normal Monoclonal Gammopathy of Undetermined Significance (MUGA) to smoldering multiple myeloma (SMM) to active multiple myeloma.
This unique expression profile is exhibited only by the BCMA cells as they have a very restricted expression pattern and are unexpressed in normal human tissues. BCMA-target therapy treatment has thus gained traction for cancer treatment and will be the choice of treatment especially for multiple myeloma. B-Cell Maturation Antigen possess co-immunoprecipitation property with a master transcription factor (IRF-4), that are mediated for myeloma cell survival. B-cell maturation antigen targeted therapies actively involve three major types of immunotherapies on the basis of product class namely, chimeric antigen receptor T-cells (CAR T Cells), bispecific antibodies, and antibody drug conjugates (ADCs). However, high cost of the treatment will be the barrier for the growth of the B-cell maturation Antigen (BCMA) targeted therapies market due to the cost involved in multiple combinational drug as well as maintenance therapy cost.
Request For Sample Copy@
https://www.coherentmarketinsights.com/insight/request-sample/190
Key players are actively developing the products which are in preclinical and clinical trials, results on these classes of therapies have demonstrated potential benefits, mainly through the safety profile offered by these therapies.
Increase in number of pipeline products are expected to boost growth of the B-cell maturation Antigen (BCMA) targeted therapies market
Market players are actively investing in research and development of novel multiple myeloma therapies to develop alternatives for existing drugs. These therapies includes chimeric antigen receptor T cells, antibody-drug conjugate, and Bi-specific antibodies. For instance, GlaxoSmithKline Plc. (GSK2857916) is developing the antibody drug conjugate drug with relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA. The robust pipeline therapies for treatment of multiple myeloma is expected to boost growth of the B-cell maturation Antigen (BCMA) targeted therapies market
High unmet needs by the recurring cases of multiple myeloma is expected to drive growth of the B-cell maturation Antigen (BCMA) targeted therapies market
The patients undergoing chemotherapy and radiation therapy are at high risk of recurrence of cancer as they develop resistance to these therapy. At present there are no treatment options are available for patients with recurrent cancer and hence the BCMA targeted therapies provides breakthrough therapeutic options for the treatment of relapsed or refractory multiple myeloma and will also cater to the current unmet needs for the treatment of relapsed or refractory myeloma, where the existing treatment modalities have proved to be clinically inefficient.
Key players operating in the development of B-cell maturation antigen (BCMA) targeted therapies market are Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd.
Get More Details On this Report:
https://www.coherentmarketinsights.com/market-insight/bcma-targeted-therapies-market-190
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Increase In Prevalence Of Multiple Myeloma Globally Is Expected To Support Growth Of Bcma Targeted Therapies Market here
News-ID: 946076 • Views: …
More Releases from Pharmaceutical Report By CMI
Rising prevalence of diabetes is a major factor driving growth of the diabetic f …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the…
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic…
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Increasing prevalence of multiple sclerosis to augment market growth
Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to…
Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2 …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the…
More Releases for BCMA
BCMA/CD3 Bispecific Antibody Market Share Driven by Breakthroughs in Targeted Im …
BCMA/CD3 Bispecific Antibody Market
BCMA/CD3 targeted drug is a bispecific antibody drug used to treat multiple myeloma. It simultaneously targets B cell maturation antigen (BCMA) and CD3 molecules on the surface of T cells, directing T cells to cancer cells, thereby enhancing the killing effect on cancer cells.
The global BCMA/CD3 Bispecific Antibody market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a…
Targeting Tomorrow: Advancements and Opportunities in the BCMA-Targeted Therapy …
In today's dynamic global economy, the B cell maturation antigen targeted therapy market is emerging as a beacon of opportunity and innovation. With rapid technological advancements, evolving consumer demands, and proactive government policies shaping the landscape, this sector is setting the stage for transformative change. Our in-depth analysis delves into historical market trends, current dynamics, and future projections, providing industry leaders, investors, and decision-makers with the strategic insights needed to…
Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Opportunitie …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global b-cell maturation antigen (bcma) targeted therapies market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future.
Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was…
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Tri …
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Trials Insight 2026 Report Analysis and Data Highlights:
* Research Methodology
* Global and Regional Market Analysis
* Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion
* Market and Drug Sales Insight 2020 Till 2026
* Approved Drug In Market: 2 Drugs
* Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026
* Future Market Assessment By Indication Till 2026
*…
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2022 | Detailed Repor …
The B-Cell Maturation Antigen (BCMA) Targeted Therapies research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market’s key players. Furthermore, the report offers insightful market data and information…
B-cell Maturation Antigen (BCMA) Targeted Therapies Market - Insights, Size, Ana …
The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline, as highlighted in a new report published by Coherent Market Insights. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA)…
